Roanna Ruiz, an analyst from Leerink Partners, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated price target was lowered to $44.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Roanna Ruiz’s rating is based on NewAmsterdam Pharma Company’s strong financial position and promising developments in their cardiovascular therapy, obicetrapib. The company has maintained a robust cash reserve of approximately $808 million, which is expected to support its operations through significant milestones, including the top-line readout of the PREVAIL CV outcomes trial in the second half of 2026 and preparations for the U.S. launch of obicetrapib.
Furthermore, the recent presentations of detailed data from the Phase 3 BROADWAY and TANDEM trials at the European Atherosclerosis Society congress, along with publications in reputable journals, have reinforced the efficacy and safety profile of obicetrapib. The drug’s unique characteristics, such as its once-daily oral administration and ability to reduce various atherogenic particles, position it as a potential blockbuster therapy for dyslipidemia. Upcoming catalysts, including an R&D Day and additional trial data presentations, are anticipated to drive further value for the stock.
In another report released on May 9, Scotiabank also maintained a Buy rating on the stock with a $52.00 price target.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is neutral on the stock.